From Medscape Diabetes & Endocrinology

Coverage from the

American Diabetes Association (ADA) 83rd Scientific Sessions

June 22 - 26, 2023; San Diego, California and virtual

June 22 - 26, 2023 San Diego, California and virtual

ADA 2023 33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells Engraftment of Vertex Pharmaceutical's VX-880 stem cell–derived islets has now been achieved in six patients, two of whom are insulin-independent at 1 year.
Medscape Medical News, July 3, 2023
ADA 2023 Triple Agonist Retatrutide Hits New Weight-Loss Highs Treatment with retatrutide, an agonist to GLP-1, GIP, and glucagon receptors in one molecule, was associated with unprecedented drops in weight from people with or without type 2 diabetes in a pair of early studies.
Medscape Medical News, June 26, 2023
ADA 2023 OASIS and PIONEER PLUS Support High-Dose Oral Semaglutide Higher doses of oral semaglutide (25 mg and 50 mg) seem to be effective in type 2 diabetes and obesity, improving upon results obtained with currently approved maximum dose of oral semaglutide 14 mg daily.
Medscape Medical News, June 25, 2023

Conference News

ADA 2023 New Uses Emerge for Obesity and Diabetes Drugs
Medscape Medical News, September 1, 2023
ADA 2023 Experts Debate Low-Carb Diets for People With Diabetes
Medscape Medical News, August 30, 2023
ADA 2023 Growth Hormone Links With Worse T2D Control in Adolescents
Medscape Medical News, August 9, 2023
ADA 2023 Time-Restricted Eating Gains for Weight and Glycemic Control
Medscape Medical News, August 3, 2023
ADA 2023 Benefits of Bariatric Surgery Persist for 12 Years
Medscape Medical News, July 28, 2023
ADA 2023 Affording the New Obesity Drugs? We Can't Afford Not to
Medscape Medical News, July 21, 2023
ADA 2023 Debate: Initial Combination Therapy for Type 2 Diabetes?
Medscape Medical News, July 13, 2023
ADA 2023 Aging and Type 1 Diabetes: 'Complete Picture' 40 Years On
Medscape Medical News, July 11, 2023
ADA 2023 Education Before Ramadan Key to Safe Fasting With Diabetes
Medscape Medical News, July 6, 2023
ADA 2023 'Artificial Pancreas' for All Type 1 Diabetes Pregnancies?
Medscape Medical News, July 5, 2023
ADA 2023 COORDINATE-Diabetes: a 'Wake-Up Call' for Many Specialties
Medscape Medical News, July 3, 2023
ADA 2023 33% of Type 1 Diabetes Patients Insulin-Free With Stem Cells
Medscape Medical News, July 3, 2023

ADA 2023 Survodutide Impresses in Phase 2 Weight-Loss Trial
Medscape Medical News, June 30, 2023
ADA 2023 Once-Weekly Basal Insulin Nears Market for Type 2 Diabetes
Medscape Medical News, June 27, 2023
ADA 2023 ADA: Screen All With Type 2 Diabetes for Fatty Liver Disease
Medscape Medical News, June 26, 2023
ADA 2023 Triple Agonist Retatrutide Hits New Weight-Loss Highs
Medscape Medical News, June 26, 2023
ADA 2023 OASIS and PIONEER PLUS Support High-Dose Oral Semaglutide
Medscape Medical News, June 25, 2023
ADA 2023 Tackle Education and Mindset to Reduce Diabetes Distress
Medscape Medical News, June 25, 2023
ADA 2023 Kids With T2D Face Dire Complications as Young Adults
Medscape Medical News, June 25, 2023
ADA 2023 New Oral GLP-1 Agonist for Obesity, Type 2 Diabetes
Medscape Medical News, June 24, 2023
ADA 2023 'Striking' Benefit of Lipid Lowering in Primary Prevention
Medscape Medical News, June 24, 2023
ADA 2023 Cagrilintide With Semaglutide: A Way to Prevent Diabesity?
Medscape Medical News, June 24, 2023
ADA 2023 SURMOUNT-2: Tirzepatide Rings Up Major Weight Loss in T2D
Medscape Medical News, June 23, 2023
ADA 2023 Obesity Takes Center Stage at Slimmed-Down Diabetes Meeting
Medscape Medical News, June 20, 2023

Medscape Diabetes© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Morning vs Afternoon Exercise Debate: A False Dichotomy
Michael Riddell, PhD
'Huge Impact' From 40 Years of DCCT/EDIC Trials Celebrated
Akshay B. Jain, MD; Bruce A. Perkins, MD, MPH; Mark Harmel, MPH, CDCES
Plant-Based or Animal-Based Diet: Which Is Better?
Akshay B. Jain, MD; Christopher Gardner, PhD
Predictive Ketone Monitoring in Type 1 Diabetes: Not Only for Sick Days
Akshay B. Jain, MD; Bruce A. Perkins, MD, MPH; Mark Harmel, MPH, CDCES
Key Data on Non-Insulin Glycemic Control in T2D From ADA 2023
Carol H. Wysham, MD
Key Data on Insulin Therapy in T2D From ADA 2023
Carol H. Wysham, MD
New T2D Medications and Technology Offer 'Bespoke' Approach
Akshay B. Jain, MD; Kevin Fernando, MSc Diabetes; Mark Harmel, MPH, CDCES
Highlights on Comorbidities of Diabetes From ADA 2023
Mona Mashayekhi, MD, PhD
Shifting Focus on Obesity: Don't Forget About Glucose
Anne L. Peters, MD
Oral GLP-1 Agonists Could Be Game Changers for Obesity
Kevin Fernando, MBChB, MSc
Who Benefits From Continuous Glucose Monitoring?
Kevin Fernando, MBChB, MSc
Bempedoic Acid: A Statin-Intolerance Savior?
Kevin Fernando, MBChB, MSc
Tirzepatide: Therapeutic Titan or Costly Cure?
Kevin Fernando, MBChB, MSc
Beta Cells From Stem Cells: Nearing a Cure for Type 1 Diabetes?
Anne L. Peters, MD

Popular News From ADA 2022

Tirzepatide Powers 'Unprecedented' Weight Loss in Obesity Trial The twincretin tirzepatide produced jaw-dropping levels of weight loss in people with obesity and no diabetes compared with placebo in the SURMOUNT-1 pivotal trial with more than 2500 participants.
Medscape Medical News, Jun 04, 2022
'Remission Is Possible' for Patients With Type 2 Diabetes In a small study conducted in India, most patients had remission type 2 diabetes at 6 months with an intervention that included a smart app that collected data and provided lifestyle advice.
Medscape Medical News, Jun 06, 2022
Self-Injury and Suicide 'All Too Common' in Type 1 Diabetes 'With a multipronged approach to awareness, education, and identification, we have the opportunity to intervene on the link between suicide and diabetes,' says the founder of an advocacy group.
Medscape Medical News, Jun 09, 2022

Previous Coverage